Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNFT NYSE:NUVB NASDAQ:PHAR NASDAQ:QURE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNFTGENFIT$3.75+0.8%$3.93$2.55▼$6.42$190.01M1.143,387 shs16,482 shsNUVBNuvation Bio$2.30-1.7%$2.20$1.54▼$3.45$782.61M1.354.25 million shs4.79 million shsPHARPharming Group$13.23+8.9%$10.89$6.73▼$17.08$906.45M0.028,921 shs11,315 shsQUREuniQure$13.28-1.3%$14.69$4.45▼$19.18$728.63M0.111.32 million shs435,425 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNFTGENFIT0.00%-1.70%0.00%-12.79%-7.64%NUVBNuvation Bio0.00%+3.60%-0.65%+10.05%-19.72%PHARPharming Group0.00%+20.71%+32.63%+31.90%+67.47%QUREuniQure0.00%-2.99%-10.75%+3.91%+86.52%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGNFTGENFIT1.5646 of 5 stars3.53.00.00.00.00.00.0NUVBNuvation Bio1.9739 of 5 stars3.60.00.00.02.43.30.0PHARPharming Group2.7788 of 5 stars3.55.00.00.02.40.00.6QUREuniQure2.4176 of 5 stars3.52.00.00.01.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNFTGENFIT 3.00Buy$13.00246.67% UpsideNUVBNuvation Bio 3.17Buy$7.33218.84% UpsidePHARPharming Group 3.00Buy$30.00126.76% UpsideQUREuniQure 2.91Moderate Buy$36.55175.19% UpsideCurrent Analyst Ratings BreakdownLatest GNFT, NUVB, QURE, and PHAR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025NUVBNuvation BioRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$6.00 ➝ $7.007/30/2025QUREuniQureCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$47.007/29/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $35.006/25/2025NUVBNuvation BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$6.006/17/2025NUVBNuvation BioRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$10.00 ➝ $6.006/11/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.006/2/2025NUVBNuvation BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$6.005/30/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.005/29/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.005/19/2025QUREuniQureCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/15/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.00 ➝ $5.00(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNFTGENFIT$76.77M2.44$0.07 per share54.33$1.50 per share2.50NUVBNuvation Bio$10.96M71.43N/AN/A$1.37 per share1.68PHARPharming Group$297.20M3.05$0.07 per share178.48$3.25 per share4.07QUREuniQure$27.12M26.87N/AN/A($0.14) per share-94.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/AN/ANUVBNuvation Bio-$567.94M-$0.63N/AN/AN/A-1,413.43%-46.14%-36.04%N/APHARPharming Group-$11.84M-$0.13N/A441.00N/A-2.19%-3.31%-1.78%10/23/2025 (Estimated)QUREuniQure-$239.56M-$3.92N/AN/AN/A-1,387.98%-1,010.74%-33.27%N/ALatest GNFT, NUVB, QURE, and PHAR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025NUVBNuvation Bio-$0.17-$0.17N/A-$0.17$0.42 million$4.83 million7/31/2025Q2 2025PHARPharming Group-$0.10$0.06+$0.16$0.06$70.36 million$93.20 million7/29/2025Q2 2025QUREuniQure-$0.89-$0.69+$0.20-$0.69$5.00 million$5.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNFTGENFITN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNFTGENFIT0.081.231.23NUVBNuvation Bio0.139.399.38PHARPharming Group0.382.792.07QUREuniQure1.539.989.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNFTGENFIT2.24%NUVBNuvation Bio61.67%PHARPharming Group0.03%QUREuniQure78.83%Insider OwnershipCompanyInsider OwnershipGNFTGENFIT4.20%NUVBNuvation Bio29.93%PHARPharming Group2.07%QUREuniQure4.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNFTGENFIT12050.00 million47.90 millionNot OptionableNUVBNuvation Bio60340.26 million238.42 millionOptionablePHARPharming Group28068.51 million67.10 millionNot OptionableQUREuniQure50054.87 million52.24 millionOptionableGNFT, NUVB, QURE, and PHAR HeadlinesRecent News About These CompaniesuniQure (NASDAQ:QURE) Upgraded at Wall Street ZenAugust 4, 2025 | americanbankingnews.comCantor Fitzgerald Predicts Weaker Earnings for uniQureAugust 3, 2025 | americanbankingnews.comLeerink Partnrs Has Bullish Estimate for uniQure Q3 EarningsAugust 3, 2025 | americanbankingnews.comWilliam Blair Has Positive Outlook for uniQure Q3 EarningsAugust 3, 2025 | americanbankingnews.comWhat is HC Wainwright's Forecast for uniQure Q3 Earnings?August 2, 2025 | americanbankingnews.comFY2027 Earnings Forecast for uniQure Issued By HC WainwrightAugust 1, 2025 | americanbankingnews.comLeerink Partnrs Has Bullish Outlook for uniQure Q4 EarningsAugust 1, 2025 | americanbankingnews.comWall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a BetJuly 31, 2025 | zacks.comBrokerages Set uniQure N.V. (NASDAQ:QURE) Price Target at $37.82July 31, 2025 | americanbankingnews.comuniQure N.V. (QURE) Q2 2025 Earnings Call TranscriptJuly 29, 2025 | seekingalpha.comuniQure Narrows Loss in Fiscal Q2July 29, 2025 | fool.comuniQure (QURE) Reports Q2 Loss, Misses Revenue EstimatesJuly 29, 2025 | zacks.comuniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company ProgressJuly 29, 2025 | globenewswire.comuniQure to Announce Second Quarter 2025 Financial ResultsJuly 22, 2025 | globenewswire.comuniQure: Price And Value Have Caught UpJune 17, 2025 | seekingalpha.comuniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy OfficerJune 11, 2025 | globenewswire.comuniQure Provides Regulatory Update on AMT-130 for Huntington's DiseaseJune 2, 2025 | globenewswire.com3 Top Genomics Stocks to Add to Your Portfolio in 2025May 21, 2025 | zacks.comWall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?May 14, 2025 | zacks.comuniQure N.V. (QURE) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNFT, NUVB, QURE, and PHAR Company DescriptionsGENFIT NASDAQ:GNFT$3.75 +0.03 (+0.81%) As of 08/8/2025 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Nuvation Bio NYSE:NUVB$2.30 -0.04 (-1.71%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$2.32 +0.02 (+0.65%) As of 08/8/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Pharming Group NASDAQ:PHAR$13.23 +1.08 (+8.89%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$12.85 -0.38 (-2.87%) As of 08/8/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.uniQure NASDAQ:QURE$13.28 -0.17 (-1.26%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$13.26 -0.01 (-0.11%) As of 08/8/2025 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
